A personalized mRNA vaccine has shown signs of meaningfully extending survival in pancreatic cancer patients. Six-year results from a small but closely tracked clinical trial support that conclusion. The findings are being presented at a major oncology conference in San Diego.
For a disease that has historically resisted immune-based treatments, the data represents a notable step forward in making the disease more responsive to immunotherapy. Donna Gustafson, who in 2020 became the first person to receive such a vaccine for pancreatic cancer, is among those still alive.
Pancreatic cancer is among the most difficult malignancies to detect and treat. No dependable early detection method exists. Unlike certain other cancers, there is no standard population-wide screening program, and the disease usually produces no symptoms until the advanced stages.
Fewer than one in eight patients survives beyond five years, and only around one in five cases can be surgically removed at the time of diagnosis. That surgical threshold is also the current requirement for entering vaccine trials of this kind.
Each vaccine is individually built from material extracted from the patient’s surgically removed tumor. The treatment does not target visible disease. Instead, it is designed to prepare the immune system to locate and neutralize residual cells that surgery may have left behind. The goal is to prevent those cells from triggering a recurrence.
All participants also completed a course of chemotherapy following their operations, in line with the established protocol for this stage of the disease.
Eight of the 16 trial participants generated a sustained immune response after vaccination, producing T cells capable of targeting cancer. Six years on, seven of those eight are alive, while two of the eight who showed no immune response have also survived. Follow-up analysis points to a probable mechanism: two T cell populations appear to play distinct but mutually reinforcing roles. One type eliminates tumor cells; the other sustains the activity of the first.
Oncologists outside the trial have called the survival gap the most meaningful signal in the data. Independent physicians involved in the review have noted that the cohort consisted of just 16 people, which limits what can be concluded. Pancreatic cancer always includes some long-term survivors who need no experimental intervention.
Whether some participants belonged to that category cannot yet be established. Some note that a shared biological trait could underlie both the immune response and the survival advantage, meaning neither factor is necessarily causing the other.
Genentech and BioNTech have moved to a larger Phase 2 study to evaluate the vaccine more broadly, and a separate team is working on a fixed-formulation vaccine targeting a protein present in the overwhelming majority of pancreatic tumors.
Different companies, such as Calidi Biotherapeutics Inc. (NYSE American: CLDI), are exploring a number of approaches to boost the immune system’s ability to combat cancer. The milestones being registered suggest that major breakthroughs could soon be attained, and patients will have several effective treatment options that can be prescribed.
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com
TinyGems is powered by IBN
